Busulphan level and early mortality in thalassaemia patients after BMT

Bone Marrow Transplantation

Volumn 23, Issue 4, 1999, Pages 307-310

  Li, C K ^a   Yuen, P M P ^a   Wong, R ^a   Pang, C P ^a   Lai, W K ^a   Law, E ^a   Shing, M M K ^a   Chik, K W ^a   Leung, T F ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Busulphan; Early mortality; Thalassaemia

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHILD; CHIMERA; CLINICAL ARTICLE; DRUG BLOOD LEVEL; GAS CHROMATOGRAPHY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERSTITIAL PNEUMONIA; INTRAVENOUS DRUG ADMINISTRATION; MASS FRAGMENTOGRAPHY; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THALASSEMIA; TREATMENT OUTCOME; VEIN OCCLUSION;

EID: 0033008722     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701584     Document Type: Article

References (15)

1. Lucarelli G. Galimberti M, Polchi P et al. Bone marrow transplantation in patients with thalassemia. New Engl J Med 1990; 322:417-421.
2. Lucarelli G, Clift RA, Galimberti M et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 1996; 87: 2082-2088.
3. Dix SP, Wingard JR, Mullins RE et al. Association of busulfan area-under-the-curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17: 225-230.
4. Slattery JT, Sanders JE, Buckner CD et al. Graft rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995: 16: 31-42.
5. Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055-3060.
6. Ljungman P, Hassan M, Bekassy AN et al. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1997; 20: 909-913.
7. Li CK, Yuen PMP, Shing MK et al. Stem cell transplant for thalassaemia patients in Hong Kong. Bone Marrow Transplant 1997; 19 (S2): 62-64.
8. Hassan M, Oberg G, Ljungman P et al. Correlation between hepatic veno-occlusive disease and busulphan levels using limited sampling model for dose estimation. Blood 1997; 90 (S1): 251a.
9. Grochow LB, Krivit W, Whitley CB, Blazar B. Busulfan disposition in children. Blood 1990; 75: 1723-1727.
10. Lin KH, Lin KS. Allogeneic bone marrow transplantation for thalassemia in Taiwan: factors associated with graft failure. Am J Ped Hem/Onc 1989; 11: 417-423.
11. Roberts IAG, Darbysnire PJ, Will AM. BMT for children with β-thalassemia major in the UK. Bone Marrow Transplant 1997; 19 (S2): 60-61.
12. Hassan M, Fasth A, Gerritsen B et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant 1996; 18: 843-850.
13. Pawlowska AB, Blazar BR, Angelucci E et al. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant 1997; 20: 915-920.
14. Essell JH, Thompson JM, Harman GS et al. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide. Blood 1992; 79: 2782-2788.
15. Yeager AM, Wagner JE, Graham ML et al. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 1992; 80: 2425-2428.